Brief: Pharming Group Says Co Receives Complete Response Letter From U.S. FDA For SNDA For Joenja (Leniolisib) In Children Aged 4 To 11 Years With Apds
01/02/2026 21:12
Feb 1 (Reuters) - Pharming Group NV PHAR.AS: PHARMING GROUP RECEIVES COMPLETE RESPONSE LETTER FROM U.S. FDA FOR SNDA FOR JOENJA® (LENIOLISIB) IN CHILDREN AGED 4 TO 11 YEARS WITH APDS PHARMING GROUP NV - FDA REQUESTS ADDITIONAL PEDIATRIC PHARMACOKINETIC DATA FOR JOENJA PHARMING GROUP NV - PLAN TO REQUEST A TYPE A MEETING WITH FDA PHARMING GROUP NV - JOENJA'S FDA APPROVAL FOR APDS IN PATIENTS 12+ UNAFFECTED Source text: ID:nGNE5BBY5h Further company coverage: PHAR.AS ((Reuters.Briefs@thomsonreuters.com;))